Kleiner heißer Tip für euch:

  --  Median survival more than doubled, with 95% of the treated animals
      surviving >110 days compared with median survival of 45 days in
      control animals;
  --  Lung metastases were reduced by 75%;
  --  Growth of primary breast tumors were reduced by 60%.


"It is rare for a single protein or target to play an important role in all three functional stages of cancer cells, let alone to do so across so many types of cancers," stated Dr. Alton Boynton. He continued, "CXCR4 offers an exceptional therapeutic opportunity both to prevent growth of primary tumors and to prevent the metastatic spread of the disease. Most importantly, the effect of anti-CXCR4 antibodies does appear to correlate with significant extensions of survival. Often, drugs that slow tumor growth do not correlate with significant extensions of survival. Strong preclinical results such as those we have presented with our anti-CXCR4 antibodies warrant the initiation of a Phase I clinical trial in patients. We plan to move this antibody into the clinic."

CXCR4 has been found to be over-expressed in more than 75% of all cancers, including breast, ovarian, lung, colon, prostate, kidney, melanoma, brain, esophageal, pancreatic, and many forms of leukemia, and childhood cancers such as acute lymphocytic leukemia and neuroblastoma. Furthermore, CXCR4 expression has been shown to correlate with poor survival, in studies by multiple independent investigators. NWBT has previously completed and reported on several in vitro preclinical studies using monoclonal antibodies to block CXCR4 receptor function, resulting in significant inhibition of cancer cell proliferation, migration and invasion in several cancer models.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company's three lead product candidates are:

DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and monoclonal antibodies to CXCR4 in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com/.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Website: www.nwbio.com/

DCVax®-Brain and DCVax®-Prostate are personalized vaccines designed to stimulate a patient\'s own immune system to fight cancer. They are therapeutic vaccines to treat existing disease. DCVax®-Brain and DCVax®-Prostate are made up of the patient\'s own dendritic cells that have been "educated" to recognize and kill cancer cells bearing the biomarkers of the patient\'s tumor. These vaccines are administered through a simple injection under the skin, similar to an insulin or flu shot.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company\'s three lead product candidates are: DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial recently cleared by the FDA ; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial recently cleared by the FDA; and monoclonal antibodies to CXCR4, which are in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company\'s ability to raise additional capital, risks related to the Company\'s ability to initiate, and enroll patients in, the planned Phase II trial of DCVax®-Brain and complete the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax®-Brain, risks related to manufacturing, risks related to the Company\'s ability to initiate, and enroll patients in, the planned Phase III trial of DCVax®-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax®-Prostate or DCVax®-Brain will demonstrate safety and efficacy, and the timely performance of third parties, and risks related to the Company\'s ability to obtain FDA clearance to initiate a Phase I clinical trial for CXCR4 and the uncertainty of the clinical trials process. Additional information on these and other factors, which could affect the Company\'s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company\'s SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


Source: Northwest Biotherapeutics, Inc.